HLB생명과학 Stock: price and insider trades · South Korea

HLB생명과학, classified in the Health Care sector, is a listed company. Its insiders report their share dealings to DART (FSS). Over the twelve months to 18 October 2026, 6 filings were filed, from 6 insiders.

No insider sold shares on the market over the period. Instead, the filings list 5 purchases, made by 5 insiders. The totals exclude 5 filings filed without an amount. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. On the buying side, the filings list 1 major shareholder among the declarants.

The latest purchase dates back some time: it was published 109 days ago, on 1 July 2026.

For context, the typical company on the same exchange (median of 2,630 companies) published 7 filings over the same period, against 6 filings here. Looking back to 2021, when coverage begins, insiders filed 16 purchases and no sales.

For comparison within the same sector, see the insider buying recorded at MAIA Biotechnology, Inc. and Cooper Companies, Inc. Every figure here comes from the filings published by DART (FSS) and describes the past, not future prices; it is not investment advice.